Ligand and Medtronic Commit $70 Million in Strategic Capital to ...
Jul 31, 2025 · Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB, plus $5 million in an equity private placement Medtronic to invest $10 …
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results
Feb 26, 2026 · Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. “We delivered strong fourth …
Ligand Pharmaceuticals Incorporated - Investor Relations
Mar 26, 2026 · Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow. We fund the clinical development and commercialization of high-value …
Ligand Reports First Quarter 2025 Financial Results
May 8, 2025 · First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel …
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
Dec 9, 2025 · Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 …
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel …
Apr 17, 2025 · About Ligand Pharmaceuticals Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this …
Ligand Pharmaceuticals Incorporated - Stock Info
Apr 17, 2026 · All 3m NASDAQ:LGND News Releases Jan 26 Feb 2 Feb 9 Feb 16 Feb 23 Mar 2 Mar 9 Mar 16 Mar 23 Mar 30 Apr 6 Apr 13 Apr 20 2021 2022 2023 2024 2025 2026 160 180 200 220 ...
Financials - Quarterly Results - Ligand Pharmaceuticals
Ligand is not responsible for, and has no role in, the development of such products or programs. Ligand owns or has rights to trademarks and copyrights that it uses in connection with the operation of its …
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
Feb 27, 2025 · Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per …
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
Nov 6, 2025 · The trademarks Ligand owns include Ligand, Captisol, NITRICIL and Zelsuvmi. Solely for convenience, some of the trademarks and copyrights referred to in this press release are listed …